This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salvana, E. M. T.
Right arrow Articles by Salata, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salvana, E. M. T.
Right arrow Articles by Salata, R. A.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, April 2009, p. 274-290, Vol. 22, No. 2
0893-8512/09/$08.00+0     doi:10.1128/CMR.00040-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules

Edsel Maurice T. Salvana1,2,3 and Robert A. Salata1* Author Bios

Division of Infectious Diseases and HIV Medicine, Department of Medicine, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio,1 Institute of Molecular Biology and Biotechnology, National Institutes of Health, University of the Philippines, Manila, Philippines,2 Section of Infectious Diseases, Department of Medicine, University of the Philippines College of Medicine and the Philippine General Hospital, Manila, Philippines3

Summary: Biologics are increasingly becoming part of routine disease management. As more agents are developed, the challenge of keeping track of indications and side effects is growing. While biologics represent a milestone in targeted and specific therapy, they are not without drawbacks, and the judicious use of these "magic bullets" is essential if their full potential is to be realized. Infectious complications in particular are not an uncommon side effect of therapy, whether as a direct consequence of the agent or because of the underlying disease process. With this in mind, we have reviewed and summarized the risks of infection and the infectious disease-related complications for all FDA-approved monoclonal antibodies and some related small molecules, and we discuss the probable mechanisms involved in immunosuppression as well as recommendations for prophylaxis and treatment of specific disease entities.

* Corresponding author. Mailing address: Division of Infectious Diseases and HIV Medicine, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106-5083. Phone: (216) 844-1988. Fax: (216) 844-2632. E-mail: ras7{at}case.edu

Clinical Microbiology Reviews, April 2009, p. 274-290, Vol. 22, No. 2
0893-8512/09/$08.00+0     doi:10.1128/CMR.00040-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»